Morbidity not increased in rheumatoid arthritis patient with profound lymphopenia following CD4 monoclonal antibody therapy: comment on the article by Isaacs et al - Reply par Isaacs, J, Waldmann, H, Hale, G, Hazleman, B

From criticism to creativity: the genesis of the ARC/BSR Clinical Trials Group. par Blake, DR, Hazleman, B, Cooper, C, Isenberg, D, Edwards, R

TREATMENT OF RHEUMATOID-ARTHRITIS WITH HUMANIZED ANTILYMPHOCYTE ANTIBODY CAMPATH-1H par Watts, R, Isaacs, J, Hale, G, Hazleman, B, Waldmann, H

CAMPATH-1H in inflammatory arthritis. par Watts, R, Isaacs, J, Hale, G, Hazleman, B, Waldmann, H

HUMANIZED MONOCLONAL-ANTIBODY THERAPY IN RHEUMATOID-ARTHRITIS par Isaacs, J, Watts, R, Hazleman, B, Hale, G, Waldmann, H

Beneficial effect of monoclonal antibody to interleukin 2 receptor on activated T cells in rheumatoid arthritis. par Kyle, V, Coughlan, R, Tighe, H, Waldmann, H, Hazleman, B

Humanized monoclonal antibody treatment in rheumatoid arthritis. par Kyle, V, Roddy, J, Hale, G, Hazleman, B, Waldmann, H

Survival of patients after lymphocytotoxic monoclonal antibody therapy for RA. par Isaacs, J, Greer, S, Symmons, D, Sharma, S, Hale, G, Waldmann, H, Hazleman, B

Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis par Isaacs, J, Clarke, A, Hazleman, B, Hale, G, Waldmann, H, Symmons, D

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H. par Isaacs, J, Hazleman, B, Chakravarty, K, Grant, J, Hale, G, Waldmann, H

Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis par Isaacs, J, Clarke, A, Hazleman, B, Hale, G, Waldmann, H, Symmons, D

A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. par Isaacs, J, Wing, MG, Greenwood, J, Hazleman, B, Hale, G, Waldmann, H

Survival of patients after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis par Isaacs, J, Clarke, A, Hazleman, B, Hale, G, Waldmann, H, Symmons, D

Humanised monoclonal antibody therapy for rheumatoid arthritis. par Isaacs, J, Watts, R, Hazleman, B, Hale, G, Keogan, M, Cobbold, S, Waldmann, H

Reprogramming the immune system: a possible therapeutic approach to established autoimmune disease. par Waldmann, H, Cobbold, S, Isaacs, J, Hale, G, Hazleman, B, Cooke, A, Lockwood, M

Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes. par Lorenzi, A, Clarke, A, Wooldridge, T, Waldmann, H, Hale, G, Symmons, D, Hazleman, B, Isaacs, J

Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. par Isaacs, J, Greer, S, Sharma, S, Symmons, D, Smith, M, Johnston, J, Waldmann, H, Hale, G, Hazleman, B

A comparison of two formulations of indomethacin ('Flexin Continus' tablets and 'Indocid' capsules) in the treatment of osteoarthritis. par Bacon, P, Luqmani, R, Bossingham, D, Daymond, T, Grahame, R, West, J, Hazleman, B, Adebajo, A, Hughes, G, Abdullah, M

A comparison of two formulations of indomethacin ('Flexin Continus' tablets and 'Indocid' capsules) in the treatment of rheumatoid arthritis. par Bacon, P, Luqmani, R, Barry, C, Foley-Nolan, D, Grahame, R, West, J, Hazleman, B, Adebajo, A, Hughes, G, Abdullah, M